"Designing Growth Strategies is in our DNA"
The global hemostatic agents market was valued at USD 3,339.4 Million in 2017 and is projected to reach USD 5,441.5 Million by 2025, exhibiting a CAGR of 6.4% in the forecast period (2018-2025).
Hemostatic agents play a major role in preventing uncontrolled hemorrhage during surgical procedures and vascular injuries. Hemostats improve hemostasis by boosting the primary hemostasis process and by vitalizing fibrin formation. The increasing incidence of hemorrhage during surgical procedures and a rising emphasis on blood loss management are driving the global hemostatic agents market.
According to data published by the Journal of Emergency Medical Services (JEMS), each year, an estimated 5.0 million people die due to traumatic and non-traumatic hemorrhage worldwide.
Combined with this, certain factors such as growth in surgical procedures, technological advancements in surgeries such as robotic surgeries, rising geriatric population and the growing prevalence of chronic conditions along with growth in trauma cases and complex surgeries are projected to boost the global market during the forecast period.
Get comprehensive study about this report by, request a free sample copy
"Combination Hemostats Product Type is Anticipated to Drive the Global Hemostatic Agents Market"
Combination hemostats offer efficient hemostasis in a shorter time due to rapid action of gelatin and thrombin. Surgiflow and Floseal are the most popular brands that are preferred in surgical hemostasis worldwide. Combination hemostats are easy to prepare, they exhibit fast action, and don’t require thawing when used during surgery.
The rising adoption of combination hemostats in surgical hemostasis is one of the major factors driving the hemostatic agents Industry. Combination hemostats accounted for a market share of 14% in 2017. Advancement in the combination hemostats and new product development with advanced technologies are expected to generate huge demand for the hemostatic agents, which will therefore boost the hemostatic agents market growth.
To get details on market share, speak to our analyst
On the basis of product type, the global market segments include combination hemostats, active hemostats, passive hemostats, and others. Combination hemostat held an rstimated 14.0% of share in the global hemostatic agents Industry in 2017. On the basis on application, the market segments include trauma, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, and others (OBGYN, Urology, transplant, etc).
In terms of application, the general surgery segment dominated the global hemostatic agents market in 2017. On the basis of end user, the market is segmented as hospitals, ambulatory surgical centers, tactical combat casualty care centers, and others.
"Growing Number of Surgical Procedures Coupled with Rapid Adoption of Hemostats is Accelerating the Growth of the Market in North America"
The market in North America was valued at USD 1,173.0 Mn in 2017. hemostatic agents market growth witnessed in the region is likely to be driven by the rising incidence of chronic disorders and the subsequently rising demand for complex surgical procedures. According to research conducted by The American College of Obstetricians and Gynecologist, the rate of postpartum hemorrhage increased by an estimated 25.9% during last decade in the U.S. Major players like Baxter adheres to the business expansion policies in emerging countries such as China, India, Brazil etc.
This would further drive the hemostatic agents market in Asia Pacific and Latin America during the forecast period. However, the market in Europe is expected to expand at a relatively lower CAGR during 2018-2025, attributed to the smaller patient pool compared to Asia Pacific region.
North America Hemostatic Agents Market, 2017
To get geographical overview of this market, request a free sample copy
"Baxter & Ethicon to Account for More Than Half of the Market in Terms of Revenue"
Baxter emerged as the leading player with the highest share in the global hemostatic agents industry in 2017, as the company is engaged in realigning its diversification strategy to improve the accessibility of its key brands. A diversified product portfolio, established brand presence, and strong R&D focus in the hemostatic agents market are responsible for its strong brand position in the market. The company also has a strong presence across the globe, through a network of distributors and subsidiaries in the Asia Pacific, Latin America, and Africa.
Hemorrhage can cause death due to blood loss as well as it increases the risk of mortality due to multi-organ failure and sepsis. Hemostatic agents play a major role in blood loss management during surgery, leading to a reduction in operating costs, rapid pace of patient recovery, and minimal hospital stays.
The report provides qualitative and quantitative insights into the hemostats industry trends and detailed analysis of global hemostatic agents market size & growth rate for all possible segments in the market. The market segments include product type, application, and end user. By product type, the global market is categorized active hemostats, passive hemostats, combination, and others. Based on the application, the market is segmented into trauma, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, and others (OBGYN, urology, transplant, and others) Various end users covered in the report are hospitals, ambulatory surgical centers, tactical combat casualty care centers, and others. Geographically, the globalhemostatic agents industry is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.
To get information on various segments, share your queries with us
Along with this, the hemostatic agents industry report analysis comprises of dynamics and competitive landscape. Various key insights provided in the report are recent industry developments such as mergers & acquisitions, an overview of pricing by key countries, technological advancements, and key industry trends.
By Product Type
· Active Hemostats
- Thrombin based Hemostats
- Fibrin Sealants
· Passive Hemostats
· Combination Hemostats
· Cardiovascular Surgery
· General Surgery
· Plastic Surgery
· Orthopedic Surgery
· Others (OBGYN, Urology, transplant, etc.)
By End User
· Ambulatory Surgical Centers
· Tactical Combat Casualty Care Centers
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Fortune Business Insights says that the hemostatic agents market was valued at USD 3,339.4 Million in 2017 and is projected to reach USD 5,441.5 Million by 2025.
In 2017, the North America Hemostatic agents market was valued at USD 1,173.0 Million.
Growing at a CAGR of 6.4%, the market will exhibit significant growth in the forecast period (2018-2025)
Passive hemostats segment is expected to be the leading segment in this market during the forecast period.
Significant increase in the number of surgeries and rising demand for topical hemostatic agents are the major factors driving the hemostatic agents market.
Baxter and Ethicon are the top players in the market.
North America is expected to hold the highest market share in the market.
Increasing emphasis on blood clot management and technological advancements are the factors that are expected to drive the adoption of hemostatic agents.
Government guideline for hemorrhage management and use of hemostatic agents in minimal invasive surgeries are trends of the hemostatic agents market.